Veracyte Inc VCYT:NASDAQ

Earnings Announcement Next Earnings date is expected on 10/22/2019
Last Price$26.19NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/21/19

Today's Change+1.52(6.16%)
Bid (Size)$26.16 (1)
Ask (Size)$26.67 (88)
Day Low / High$24.60 - 26.30
Volume962.0 K
 

View Biotechnology IndustryPeer Comparison as of 10/21/2019

 

Veracyte Inc ( NASDAQ )

Price: $26.19
Change: +1.52 (6.16%)
Volume: 962.0 K
4:00PM ET 10/21/2019
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $60.97
Change: +1.26 (2.11%)
Volume: 142.7 K
4:00PM ET 10/21/2019
 
 

Audentes Therapeutics Inc ( NASDAQ )

Price: $27.18
Change: +0.33 (1.23%)
Volume: 278.8 K
4:00PM ET 10/21/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

MT Newswires After-Hours News Movers
5:54PM ET 10/21/2019 MT Newswires

Some of the stocks moving on news-driven events in Monday's after-hours include: NLNK, +7.38% AMTD, +5.31% CDNS, +4.84% WSFS, +1.79% UPS, +1.58% ZION,...

Veracyte's Data Shows Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis
5:11PM ET 10/21/2019 MT Newswires

Veracyte (VCYT) said on Monday data showed the clinical validity of its next-generation Percepta Genomic Sequencing Classifier (GSC) and the clinical...

Insider Trends: Insider at Veracyte Converts Options in Mist of 90-Day Buying Trend
4:08PM ET 9/20/2019 MT Newswires

On Sep 18, 2019, Keith Kennedy, COO / CFO, exercised options for 22,365 shares in Veracyte (VCYT) for $167,067. Kennedy, subsequent to the transactions...

Insider Trends: Veracyte Insider Extends 90-Day Selling Trend
5:47PM ET 9/12/2019 MT Newswires

Bonnie H Anderson, Director and Chairman & CEO, sold 8,000 shares of Veracyte (VCYT) on Sep 10, 2019, for $196,114. Subsequent to the Form 4 filing with...

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Phone+1.650.243.6300
Number of Employees270
Recent SEC Filing10/11/20194
Chairman & Chief Executive OfficerBonnie H. Anderson
Chief Operating & Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy
Chief Information OfficerAshish Kheterpal

Company Highlights

Price Open$24.84
Previous Close$26.19
52 Week Range$9.20 - 31.18
Market Capitalization$1.3 B
Shares Outstanding48.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/22/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.29
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-11.01%
Return on Equity-10.26%

Analyst Ratings as of 07/31/2019

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset